ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-24

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

NCT05822284

Non-small Cell Lung Cancer

NOT_YET_RECRUITING

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358

Lung Cancer, Nonsmall Cell

ACTIVE_NOT_RECRUITING

ctDNA as a Biomarker for Treatment in Advanced NSCLC

NCT05486988

Non-small Cell Lung Cancer

UNKNOWN

ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

NCT03172156

Non-small Cell Lung Cancer Stage I

COMPLETED

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

NCT02804100

Carcinoma, Non-Small-Cell Lung Bronchial Neoplasms Carcinoma, Bronchogenic +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Evidence suggests that circulating tumor DNA (ctDNA) analysis can noninvasively identify minimal residual disease (MRD) in clinical oncology. The researches will be sharply increased about ctDNA potential clinical application in the near future. In the early stage of NSCLC, ctDNA has been indicated to identify those at high risk of recurrence after radical surgery. And this study will focus on those patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months). 10ml plasma will be collected every three months until disease progression to interrogate ctDNA by high-depth panel sequencing, exploring its prediction value about the risk of progression. Meanwhile, the investigators would like to explore the lead time of detectable ctDNA before regular imaging finding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Lung Non-Small Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-informed group)

The ctDNA detection will be performed using a tumor-informed analysis approach. This method requires the availability of tumor tissue samples or a fixed-panel next-generation sequencing (NGS) test.

ctDNA detection

Intervention Type DIAGNOSTIC_TEST

High-depth sequencing method is used to detecting ctDNA.

Advanced NSCLC patients with long-term benefit after first-line immunotherapy (Tumor-agnostic group)

The ctDNA detection will be performed using a tumor-agnostic analysis. This method does not require tumor tissue samples or an NGS testing panel, or in cases where tissue samples are available but fail to meet quality control standards.

ctDNA detection

Intervention Type DIAGNOSTIC_TEST

High-depth sequencing method is used to detecting ctDNA.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ctDNA detection

High-depth sequencing method is used to detecting ctDNA.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Advanced non-small cell lung cancer (stage IIIB-IV), pathological types limited to squamous cell carcinoma or non-squamous cell carcinoma, driver gene mutations (EGFR/ALK/ROS1) were negative
* General condition: ECOG score 0 or 1
* First-line monotherapy or combination immunotherapy
* The long-term benefit of immunotherapy was defined as PFS=12months
* Tumor tissue samples can be obtained at the time of enrollment, and at least 5 \~ 10 sections can be generated, and the pathological report indicates that the overall tumor content is not less than 10% or NGS testing with a fixed-panel is available; or no tumor tissue is available.
* At least one measurable lesion (except patients with CR after first-line treatment) can be evaluated according to RECIST1.1 standard.
* Have self-awareness, be able to understand the research scheme and voluntarily participate in the study, and can sign the informed consent form
* Have good compliance, be able to cooperate with the collection of specimens from each node and provide corresponding clinical information.

Exclusion Criteria

* Serious primary diseases of the heart, liver and kidney
* Other malignant tumors within 3 years prior to diagnosis of NSCLC
* Women in pregnancy and lactation
* The active stage of human immunodeficiency virus (HIV) infection
* Patients with active systemic infection, pneumonia, tuberculosis, pericarditis
* Patients who cannot understand the content of the experiment and cannot cooperate and refuse to sign informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No